Intestinal lipoprotein assembly in apobec-1-/- mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins.
Mammalian enterocytes express apolipoprotein (apo)B-48, which is produced after posttranscriptional RNA editing of the nuclear apoB-100 transcript by the catalytic deaminase apobec-1. Earlier studies in apobec-1-/- mice revealed an apoB-100-only lipoprotein profile but no gross defects in triglyceride absorption. However, subtle defects may have been obscured by the mixed genetic background. In addition, the intrinsic susceptibility to proteolytic degradation of intestinal apoB-100 and apoB-48 has been questioned. Accordingly, we examined triglyceride absorption, intestinal apoB expression, and lipoprotein secretion in apobec-1-/- mice backcrossed into a C57BL/6 background. Inbred apobec-1-/- mice absorb triglyceride normally, yet secrete triglyceride-rich lipoproteins more slowly than wild-type congenic controls. There was comparable induction of apoB synthesis in response to fat feeding in both genotypes, but apoB-100 was preferentially retained and more extensively degraded than apoB-48. By contrast, synthesis, secretion, and content of apo A-IV were indistinguishable in apobec-1-/- and wild-type mice with 100% recovery, suggesting no degradation of this apoprotein in either genotype. Newly secreted lipoproteins from isolated enterocytes of wild-type mice revealed apoB-48 in both high-density lipoproteins and very low-density lipoproteins. By contrast, apobec-1-/- mice secreted apoB-100-containing particles that were almost exclusively in the low and very low-density lipoproteins range with no apoB-100-containing high-density lipoproteins. These studies establish the existence of preferential degradation of intestinal apoB-100 and subtle defects in triglyceride secretion in apobec-1-/- mice, coupled with a shift to the production of larger particles, findings that suggest an important divergence in intestinal lipoprotein assembly pathways with the different isoforms of apoB.
Xie
Yan
Y
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Nassir
Fatiha
F
Luo
Jianyang
J
Buhman
Kimberly
K
Davidson
Nicholas O
NO
D000071479:APOBEC-1 Deaminase; D000818:Animals; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001054:Apolipoproteins A / Q000378:metabolism; D001055:Apolipoproteins B / Q000032:analysis / Q000096:biosynthesis / Q000502:physiology; D003564:Cytidine Deaminase / Q000172:deficiency* / Q000502:physiology; D004041:Dietary Fats / Q000493:pharmacokinetics; D020895:Enterocytes / Q000737:chemistry / Q000378:metabolism; D007163:Immunosorbent Techniques; D007178:Inbreeding; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000737:chemistry; D008074:Lipoproteins / Q000032:analysis / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000032:analysis; D008077:Lipoproteins, LDL / Q000032:analysis; D008079:Lipoproteins, VLDL / Q000032:analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008823:Micelles; D010316:Particle Size; D017393:RNA Editing; D014280:Triglycerides / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics
D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D004041:Dietary Fats; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D008823:Micelles; D014280:Triglycerides; C022205:apolipoprotein A-IV; D000071479:APOBEC-1 Deaminase; C000605090:Apobec1 protein, mouse; D003564:Cytidine Deaminase